• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatic first-pass metabolism in liver disease.

作者信息

Blaschke T F, Rubin P C

出版信息

Clin Pharmacokinet. 1979 Nov-Dec;4(6):423-32. doi: 10.2165/00003088-197904060-00002.

DOI:10.2165/00003088-197904060-00002
PMID:391462
Abstract
摘要

相似文献

1
Hepatic first-pass metabolism in liver disease.肝脏疾病中的肝首过代谢
Clin Pharmacokinet. 1979 Nov-Dec;4(6):423-32. doi: 10.2165/00003088-197904060-00002.
2
Clearance by the liver: current concepts in understanding the hepatic disposition of drugs.肝脏清除：理解药物肝脏处置的当前概念。
Semin Liver Dis. 1983 Nov;3(4):285-97. doi: 10.1055/s-2008-1040781.
3
Altered drug metabolism and elevated serum bile acids in liver disease: a unified pharmacokinetic explanation.肝病中药物代谢改变与血清胆汁酸升高：一种统一的药代动力学解释
Gastroenterology. 1980 Jan;78(1):177-9.
4
Drug administration in hepatic disease.肝脏疾病中的药物给药
N Engl J Med. 1983 Dec 29;309(26):1616-22. doi: 10.1056/NEJM198312293092605.
5
Hepatic clearance measurements and pharmacokinetics.肝脏清除率测定与药代动力学。
Pharmacology. 1979;19(3):105-10. doi: 10.1159/000137296.
6
[Changes in drug kinetics in liver diseases and their importance in rational pharmacotherapy].[肝脏疾病中药物动力学的变化及其在合理药物治疗中的重要性]
Pol Tyg Lek. 1977 Dec 26;32(52):2057-60.
7
Drug pharmacokinetics in cardiac and hepatic disease.
Annu Rev Pharmacol Toxicol. 1980;20:389-413. doi: 10.1146/annurev.pa.20.040180.002133.
8
First-pass elimination. Basic concepts and clinical consequences.首过消除。基本概念及临床后果。
Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. doi: 10.2165/00003088-198409010-00001.
9
First-pass metabolism.首过代谢
Practitioner. 1983 Oct;227(1384):1619-27.
10
Clinical pharmacokinetics.
Annu Rev Pharmacol Toxicol. 1979;19:105-27. doi: 10.1146/annurev.pa.19.040179.000541.

引用本文的文献

1
To use or not to use: Safety of selected painkillers in patients with chronic liver diseases.用还是不用：慢性肝病患者中某些止痛药的安全性
Clin Exp Hepatol. 2025 Jun;11(2):113-120. doi: 10.5114/ceh.2025.151745. Epub 2025 Jun 25.
2
The assessment and management of pain in cirrhosis.肝硬化疼痛的评估与管理
Curr Hepatol Rep. 2018 Mar;17(1):42-51. doi: 10.1007/s11901-018-0389-7. Epub 2018 Feb 22.
3
The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations.

本文引用的文献

1
The disposition of propranolol. I. Elimination during oral absorption in man.普萘洛尔的处置。I. 人体口服吸收过程中的消除
Pharmacology. 1972;7(3):159-68. doi: 10.1159/000136285.
2
Kidney disease and drug metabolism.肾脏疾病与药物代谢
Med Clin North Am. 1974 Sep;58(5):1059-62. doi: 10.1016/s0025-7125(16)32101-0.
3
Route of administration and drug disposition.给药途径与药物处置
肝硬化患者中镇痛药的治疗应用：一项文献综述与循证推荐
Hepat Mon. 2014 Oct 11;14(10):e23539. doi: 10.5812/hepatmon.23539. eCollection 2014 Oct.
4
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.伴有肝损伤的患者应用口服直接因子 Xa 抑制剂利伐沙班、阿哌沙班和依度沙班以及凝血酶抑制剂达比加群酯的抗凝治疗。
Clin Pharmacokinet. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0.
5
Analgesics in patients with hepatic impairment: pharmacology and clinical implications.肝功能损害患者的镇痛药：药理学和临床意义。
Drugs. 2012 Aug 20;72(12):1645-69. doi: 10.2165/11635500-000000000-00000.
6
Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis.肝硬化患者的潜在药物-药物相互作用和药物不良反应。
Eur J Clin Pharmacol. 2012 Feb;68(2):179-88. doi: 10.1007/s00228-011-1105-5. Epub 2011 Aug 13.
7
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.肝功能不全患者的药代动力学及剂量调整
Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61. doi: 10.1007/s00228-008-0553-z. Epub 2008 Sep 2.
8
A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.老年患者硬膜外利多卡因的群体药代动力学模型：小剂量多巴胺的影响。
Ther Drug Monit. 2008 Jun;30(3):379-89. doi: 10.1097/FTD.0b013e3181778fa3.
9
Effect of hepatic insufficiency on pharmacokinetics and drug dosing.肝功能不全对药代动力学及给药剂量的影响。
Pharm World Sci. 1998 Oct;20(5):183-92. doi: 10.1023/a:1008656930082.
10
Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.新型血管紧张素转换酶抑制剂螺普利单次口服剂量在慢性肝病患者中的药代动力学及血流动力学效应
Eur J Clin Pharmacol. 1993;45(3):247-53. doi: 10.1007/BF00315391.
Drug Metab Rev. 1974;3(2):185-99. doi: 10.3109/03602537408993742.
4
Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease.酒精性肝病中脾床和肠系膜床门体分流的定量分析。
Am J Med. 1972 Dec;53(6):715-22. doi: 10.1016/0002-9343(72)90188-x.
5
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.苯巴比妥治疗后猴子体内安替比林和d-普萘洛尔清除率增加。酶诱导和肝血流量增加的相对作用。
J Clin Invest. 1974 Apr;53(4):1101-7. doi: 10.1172/JCI107647.
6
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.
J Pharmacol Exp Ther. 1975 Dec;195(3):416-23.
7
Clinical pharmacokinetics of hydrallazine.
Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29. doi: 10.2165/00003088-197702050-00001.
8
Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings].正常受试者和肝硬化患者中普萘洛尔处置的生物学决定因素[会议论文集]
Br J Clin Pharmacol. 1977 Oct;4(5):630P. doi: 10.1111/j.1365-2125.1977.tb00802.x.
9
Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.高血压患者在肾功能正常和受损情况下吲哚洛尔的药代动力学及肝脏摄取率
J Clin Pharmacol. 1977 Aug-Sep;17(8-9):501-8. doi: 10.1002/j.1552-4604.1977.tb05643.x.
10
Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.
J Pharmacokinet Biopharm. 1977 Jun;5(3):193-205. doi: 10.1007/BF01065395.